These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28890480)

  • 1. Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension.
    Satoh M; Aso K; Nakayama T; Saji T
    Endocr J; 2017 Dec; 64(12):1173-1180. PubMed ID: 28890480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender-related differences in pulmonary arterial hypertension targeted drugs administration.
    Marra AM; Benjamin N; Eichstaedt C; Salzano A; Arcopinto M; Gargani L; D Alto M; Argiento P; Falsetti L; Di Giosia P; Isidori AM; Ferrara F; Bossone E; Cittadini A; Grünig E
    Pharmacol Res; 2016 Dec; 114():103-109. PubMed ID: 27771466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune thyroid disease in children and adolescents with idiopathic pulmonary arterial hypertension.
    Satoh M; Aso K; Nakayama T; Naoi K; Ikehara S; Uchino Y; Shimada H; Takatsuki S; Matsuura H; Saji T
    Circ J; 2010 Feb; 74(2):371-4. PubMed ID: 20009390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
    Hall SM; Davie N; Klein N; Haworth SG
    Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin antagonism in pulmonary arterial hypertension.
    Lee SH; Channick RN
    Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone.
    Chadha C; Pritzker M; Mariash CN
    Endocr Pract; 2009 Mar; 15(2):116-21. PubMed ID: 19289321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
    Menon AA; Sahay S; Braverman LE; Farber HW
    Lung; 2019 Dec; 197(6):761-768. PubMed ID: 31696306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
    Beghetti M
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.
    Rubenfire M; Huffman MD; Krishnan S; Seibold JR; Schiopu E; McLaughlin VV
    Chest; 2013 Oct; 144(4):1282-1290. PubMed ID: 23744060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.
    Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R
    Respiration; 2016; 91(1):9-17. PubMed ID: 26492415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary arterial hypertension: a current review of pharmacological management.
    Sahni S; Ojrzanowski M; Majewski S; Talwar A
    Pneumonol Alergol Pol; 2016; 84(1):47-61. PubMed ID: 26693827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension.
    Ogawa A; Satoh T; Tamura Y; Fukuda K; Matsubara H
    Am J Cardiol; 2017 May; 119(9):1479-1484. PubMed ID: 28267959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary arterial hypertension : a comprehensive review of pharmacological treatment.
    Berman Rosenzweig E; Barst RJ
    Treat Respir Med; 2006; 5(2):117-27. PubMed ID: 16512692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening.
    Levy M; Bonnet D; Mauge L; Celermajer DS; Gaussem P; Smadja DM
    PLoS One; 2013; 8(6):e65114. PubMed ID: 23762293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents.
    Yamamoto K; Takeda Y; Takeda Y; Naniwa T; Narita H; Ohte N
    BMC Res Notes; 2014 Jun; 7():359. PubMed ID: 24920465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
    Rhee RL; Gabler NB; Praestgaard A; Merkel PA; Kawut SM
    Arthritis Rheumatol; 2015 Sep; 67(9):2457-65. PubMed ID: 26016953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.